- Rebranding marks shift from fertility clinics to full-lifecycle care
- IPO prep in Hong Kong underway since 2025
Huasheng Health, a Chinese women’s health company that started out in pregnancy and fertility services, completed a Series E financing round for an undisclosed amount on May 17 as it pushes deeper into AI-driven, full-lifecycle digital healthcare.
Backed by Puhua Capital, healthcare-focused Xiaochi Fund and Jiaxing Xinyi Ventures during the latest raise, the company did not disclose deal terms.
According to data released by China’s National Bureau of Statistics, cited by China Central Television (CCTV) in September 2021, infertility rates among couples of reproductive age in China stood at 12%-18%, meaning roughly one in every six to seven couples faces fertility challenges.
“Demand for reproductive and fertility healthcare in China is real, urgent and sustainable,” lead investor Puhua Capital said in a press release, pointing to shifting demographics and policy support for larger families.
The Huzhou-based startup also announced a rebrand from “Huasheng Care” to Huasheng Health, positioning itself as a broader digital healthcare platform covering both women and men and modelled on US-listed Hims & Hers Health.
Founded in 2014, the company initially focused on reproductive and pregnancy assistance services through its “Haoyunbang” platform.
That business line remains a core asset, now serving more than 12 million users. It has since expanded into a network of nearly 30 medical institutions across 15 cities.
Since 2019, Huasheng has embedded AI into its in-house “Huasheng Cloud” system, supporting patient education, consultations, medical record generation and operations management.
The company says revenue has doubled annually for six straight years, with 2026 expected to exceed 1 billion yuan ($147 million), largely driven by out-of-pocket payments.
After the latest funding, Huasheng plans to extend beyond fertility into weight management, aesthetic medicine and anti-aging services, building what it describes as an online-to-offline care loop.
The company has been preparing for a Hong Kong IPO since 2025, public records show.
